多肽CRDMO平台
目录肽
大奖888生化目录肽版块全新呈现，致力于打造全球最全面的多肽供应平台！我们专业的学术团队将时刻追踪最新最热的研究动向，帮助您发现实际需求，并以最高质量标准提供您所需要的产品。我们将我们将不定期更新产品列表，为您最大限度地节约科研时间，敬请广大客户朋友关注！
LHRH-022B
Cetrorelix
Ac-D-2-Nal-4-chloro-D-Phe-β-(3-pyridyl)-D-Ala-Ser-Tyr-D-Cit-Leu-Arg-Pro-D-Ala-NH2\nAcetate salt
Ac-D-2-Nal-4-chloro-D-Phe-β-(3-pyridyl)-D-Ala-Ser-Tyr-D-Cit-Leu-Arg-Pro-D-Ala-NH2\nAcetate salt
Size：5
P1(RMB)：2020
MW：1431.06
One letter sequence：Ac-D-2-Nal-4-chloro-D-F-β-(3-pyridyl)-D-ASY-D-Cit-LRPa-NH2
Molecular Formula：C70H92ClN17O14
Description：GnRH antagonist. CAS Number (cetrorelix acetate): 145672-81-7.\nThis peptide is offered and sold solely for uses reasonably related to the development and submission of information under a Federal law which regulates the manufacture, use or sale of drugs (the “Bolar Exemption”). Bachem cannot be made liable for any infringement of intellectual property rights. It is the sole and only responsibility of the purchaser or user of this product to comply with the relevant national rules and regulations.\nA highly modified luteinizing hormone-releasing hormone (LHRH) decapeptide with a terminal amide group, this peptide is a LHRH antagonist. It regulates the expression of Galphas and Galphai protein subunits and adenylate cyclase activity in ovary, breast and pituitary. Cetrorelix competitively inhibits LHRH receptor in the pituitary gland to suppress ovarian and testicular functions.
Literature Reference：T.Reissmann et al., Hum. Reprod. Update, 6, 322 (2000)\nG.Emons et al., Endocr. Relat. Cancer, 10, 291 (2003)\nD.B.Shapiro and D.Mitchell-Leef, Minerva Ginecol., 55, 373 (2003)\nC.Gründker et al., Eur. J. Endocrinol., 151, 141 (2004)
Cas：120287-85-6
P1(RMB)：2020
MW：1431.06
One letter sequence：Ac-D-2-Nal-4-chloro-D-F-β-(3-pyridyl)-D-ASY-D-Cit-LRPa-NH2
Molecular Formula：C70H92ClN17O14
Description：GnRH antagonist. CAS Number (cetrorelix acetate): 145672-81-7.\nThis peptide is offered and sold solely for uses reasonably related to the development and submission of information under a Federal law which regulates the manufacture, use or sale of drugs (the “Bolar Exemption”). Bachem cannot be made liable for any infringement of intellectual property rights. It is the sole and only responsibility of the purchaser or user of this product to comply with the relevant national rules and regulations.\nA highly modified luteinizing hormone-releasing hormone (LHRH) decapeptide with a terminal amide group, this peptide is a LHRH antagonist. It regulates the expression of Galphas and Galphai protein subunits and adenylate cyclase activity in ovary, breast and pituitary. Cetrorelix competitively inhibits LHRH receptor in the pituitary gland to suppress ovarian and testicular functions.
Literature Reference：T.Reissmann et al., Hum. Reprod. Update, 6, 322 (2000)\nG.Emons et al., Endocr. Relat. Cancer, 10, 291 (2003)\nD.B.Shapiro and D.Mitchell-Leef, Minerva Ginecol., 55, 373 (2003)\nC.Gründker et al., Eur. J. Endocrinol., 151, 141 (2004)
Cas：120287-85-6
